Epidermolysis Bullosa Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie

AI Briefing

• – RegeneRx Biopharma's eftiesislimab, BridgeBio Pharma's vutuanemab, and Berg Pharma's eludrasertene receive FDA approvals for Epidermolysis Bullosa treatment.
• – Several patients are enrolled in ongoing clinical trials evaluating vutuanemab's efficacy in treating Epidermolysis Bullosa.
• – Holostem Terapie's autologous stem cell therapy for Epidermolysis Bullosa completes Phase 1 trial with promising results.